Clinical Data and Presentations
DateTitle
A2a
18 April 2018 Inhibition of A2aR by AZD4635 induces anti-tumor immunity alone and in combination with ant-PD-L1 in preclinical models
15 April 2019 Evidence of immune activation in the first-in-human Phase 1a dose escalation study of AZD4635 in patients with advanced solid tumors
15 April 2019 The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells
M1
27 October 2018 Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers
29 March 2019 Basal forebrain volumes predict circuit specific functional sensitivity to the muscarinic M1 receptor antagonist biperiden on cognition
Asthma
22 May 2019 The Combination of Indacaterol/Glycopyrronium/Mometasone Furoate is Superior to High-Dose Salmeterol/Fluticasone Propionate in Improving Lung Function in Patients with Asthma
22 May 2019 The Efficacy of the Combination Indacaterol/Glycopyrronium/Mometasone Furoate is Independent of Time of Dosing in Patients with Asthma
30 September 2019 Lung function, pharmacokinetics, and tolerability of indacaterol maleate and acetate in asthma patients
30 September 2019 Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a fixed-dose combination in healthy subjects
30 September 2019 Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate as a fixed-dose combination in Japanese and Caucasian healthy subjects
30 September 2019 Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma
1 October 2019 Mometasone furoate delivered via Breezhaler® and Twisthaler® in patients with asthma
1 October 2019 Indacaterol/glycopyrronium/mometasone furoate combination shows consistent lung function benefits in patients with asthma
1 October 2019 Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings